


Applicants: Arlindo L. Castelhana et al.  
Serial No.: 10/718,280  
Filed : November 20, 2003  
Page 2

**Amendments to the Claims**

Please cancel claims 42-50 under the provisions of 37 C.F.R. §1.121, as set forth in the Federal Register on June 30, 2003, as follows:

1-54. (Canceled)

55. (Previously Presented) A pharmaceutical composition comprising the compound having the structure:



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

56. (Previously Presented) The pharmaceutical composition of claim 55, further comprising at least one of either a steroid,  $\beta$ 2 agonist, glucocorticoid, leukotriene antagonist, or an anticholinergic agonist.

57. (Previously Presented) The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is formulated for administration as a periocular, retrobulbar or intraocular injection.

Applicants: Arlindo L. Castelhana et al.  
Serial No.: 10/718,280  
Filed : November 20, 2003  
Page 3

58. (Previously Presented) The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is formulated for systemic administration.
59. (Previously Presented) The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is formulated for administration as a surgical irrigating solution.
60. (Previously Presented) A packaged pharmaceutical composition for treating a subject suffering from a disease associated with an A1 adenosine receptor in a subject, comprising the pharmaceutical composition of claim 55 and instructions for using the composition for treating the subject.